At a glance
ClinicalIndex Comparison Record- ✓Cerebral infarction or TIA with acute ischemic brain lesion on MRI within 2 weeks of onset
- ✓Age over 35 years
- ✓Significant focal stenosis in M1 segment of middle cerebral artery (MCA) or basilar artery (BA) with acute ischemic lesions in the territory of the stenosed artery
- ✕Contraindications to antiplatelet therapy
- ✕Cardiac embolic sources including prosthetic valve, atrial fibrillation/flutter, cardiac thrombus, cardiomyopathy, or recent myocardial infarction (within 4 weeks)
- ✕More than 50% stenosis in the parent artery of symptomatic stenosis
- ✕Bleeding diathesis
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Trial for Efficacy and Safety of Cilostazol on the Progression of Symptomatic Intracranial Stenosis Comparing Clopidogrel
In Brief
A Phase 4 clinical trial evaluating clopidogrel and Cilostazol for Cerebral Infarction and Atherosclerosis. Completed, enrolled 457 participants across 19 sites in 4 countries.
Detailed Summary
This study will recruit 480 acute stroke patients with symptomatic intracranial stenosis (M1 segment of Middle cerebral artery (MCA) or basilar artery). They will be randomly assigned into cilostazol group or clopidogrel group. Every patients will take 100mg of aspirin a day additionally. The primary outcome variable of this study is Progression rate of symptomatic intracranial stenosis on magnetic resonance angiogram (MRA).
Study Details
Timeline
Interventions
Clopidogrel 75mg once a day plus placebo of cilostazol twice a day
Cilostazol 100mg twice a day plus placebo of clopidogrel once a day